Table 1.
Baseline characteristics
| Characteristics | Total population (n = 2300) | Men (n = 1729) | Women (n = 571) | P‐value |
|---|---|---|---|---|
| Age (years) | 62 ± 13 | 63 ± 12 | 61 ± 14 | <0.001 |
| Cardiovascular risk factors | ||||
| Diabetes mellitus | 503 (22%) | 398 (23%) | 105 (18%) | 0.02 |
| Stroke | 249 (11%) | 190 (11%) | 59 (10%) | 0.66 |
| Cardiac history | ||||
| Ischaemic heart disease | 1422 (62%) | 1191 (69%) | 231 (41%) | <0.001 |
| Ischaemic CMP a | 1217 (55%) | 1028 (63%) | 189 (34%) | <0.001 |
| Non‐ischaemic CMP a | 794 (36%) | 487 (30%) | 307 (56%) | <0.001 |
| Preserved LV function a | 109 (5%) | 68 (4%) | 41 (7%) | <0.01 |
| NYHA class ≥II b | 1535 (73%) | 1132 (72%) | 403 (77%) | 0.05 |
| Atrial fibrillation | 615 (27%) | 495 (29%) | 120 (21%) | <0.001 |
| NSVT | 241 (11%) | 178 (10%) | 63 (11%) | 0.62 |
| Creatinine (μmol/L) | 91 (76–112) | 94 (80–116) | 78 (65–97) | <0.001 |
| QRS duration (ms) | 126 ± 32 | 127 ± 32 | 124 ± 33 | 0.04 |
| Left bundle branch block | 575 (25%) | 399 (23%) | 176 (31%) | <0.001 |
| LVEF (%) c | 32 ± 12 | 31 ± 12 | 32 ± 12 | 0.48 |
| Medication at discharge | ||||
| ACEi/ARB | 1885 (82%) | 1448 (84%) | 437 (77%) | <0.001 |
| Beta‐blocker | 1922 (84%) | 1442 (83%) | 480 (84%) | 0.71 |
| MRA | 823 (36%) | 583 (34%) | 240 (42%) | <0.001 |
| Diuretics | 1312 (57%) | 942 (55%) | 370 (65%) | <0.001 |
| Amiodarone | 297 (13%) | 235 (14%) | 62 (11%) | 0.09 |
| Digoxin | 257 (11%) | 177 (10%) | 80 (14%) | 0.01 |
| Device type and device indication | ||||
| ICD | 1648 (72%) | 1270 (74%) | 378 (66%) | 0.001 |
| CRT‐D | 652 (28%) | 459 (27%) | 193 (34%) | |
| Primary prevention | 1494 (65%) | 1089 (63%) | 405 (71%) | 0.001 |
| Secondary prevention | 806 (35%) | 640 (37%) | 166 (29%) | |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CMP, cardiomyopathy; CRT‐D, resynchronization therapy; ICD, implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NSVT, non‐sustained ventricular tachycardia; NYHA, New York Heart Association.
a
Based on N = 2195.
b
Based on N = 2092.
c
Based on N = 2024.